None listed
Conditions
Interventions
None listed
Sponsors
Pharmanza Herbal
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients above 60 years of age belonging to either gender (males/females) 2. Fasting plasma glucose 3. Patients willing to follow all trial procedures.
Exclusion criteria
Exclusion criteria: Patients suffering from systemic illness necessitating long term drug treatment rheumatoid arthritis psychoneuroendocrinal disorders Patients having any cardiovascular disease Patients with diabetes mellitus HbA1c >6.5 FBS >126 mg/dl and PPBS > 200 mgdl Patients with the concurrent hepatic disorder (defined as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >2 times upper normal limit, total bilirubin alkaline phosphates (ALP) >2 times the upper normal limit Renal disorder is defined as S Creatinine > 3 mgdl Patients with pulmonary dysfunction bronchial asthma and chronic obstructive pulmonary disease COPD Inflammatory bowel disease Severe dementia Severe infection Non-ambulatory patients or any other condition that may jeopardize the study Subjects who are currently alcoholics and/or use psychoactive substances patients who have completed participation in any other clinical trial during the past 6 months Subjects who have a history of allergy hypersensitivity or intolerance to investigational product Subjects who have a history or evidence of active infection or febrile illness within 7 days prior to the screening assessment and subjects who have a history of any other clinically significant disease or disorder that, in the opinion of the principal investigator, may place the subject at risk due to participation in the study, or may influence the results of the study or the subject ability to complete the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3 minute walk test hand grip strength test MMSE Telomere length, cellular senescence -PBMC Sirt 1, Sirt 6, NAD+ and DNA methylation assayTimepoint: 0, 12 and 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| safety testing LFT RFTTimepoint: 0 and 24 weeks | — |
Countries
India
Contacts
Public ContactDr Aboli Girme
Pharmanza Herbal Private Limited
Outcome results
None listed